Levetiracetam Injection, Solution, Concentrate
Product Images NDC 51224-013

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 51224-013). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tagi Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 01

A bar graph showing the percentage of patients for three groups: Placebo with 7.4%, Levetiracetam 1,000 mg/day with 37.1%, and Levetiracetam 3,000 mg/day with 39.6%. The graph compares patient response rates across these three groups.*

FDA Label Image

Image 02

A vertical bar chart comparing the percentage of patients in three groups: placebo (6.3%, N=111), levetiracetam 1,000 mg/day (20.8%, N=106), and levetiracetam 2,000 mg/day (35.2%, N=105). The y-axis represents the percentage of patients, ranging from 0% to 45%. Each bar is labeled with its corresponding percentage and asterisk symbol.*

FDA Label Image

Image 03

A bar graph comparing the percentage of patients for Placebo (N=104) and Levetiracetam 3,000 mg/day (N=180). The y-axis shows the percentage of patients, with the Placebo group at 14.4% and the Levetiracetam group at 39.4%, with an asterisk above the Levetiracetam bar indicating statistical significance.*

FDA Label Image

Image 04

A bar chart comparing the percentage of patients between two groups: Placebo (N=97) with 19.6% and Levetiracetam (N=101) with 44.6%. The Y-axis represents the percentage of patients, ranging from 0% to 45%, illustrating higher patient outcomes associated with Levetiracetam in this comparison.*

FDA Label Image

Image 05

A bar chart comparing the percentage of patients for placebo (19.6%) and levetiracetam (43.1%). The x-axis labels the groups with their sample sizes (Placebo N=51, Levetiracetam N=58), and the y-axis shows the percentage of patients from 0% to 45%. Asterisk (*) is shown on the levetiracetam bar indicating statistical significance.*

FDA Label Image

Image 06

A bar chart comparing percentage of patients between two groups: Placebo (N=84) at 45.2% and Levetiracetam (N=79) at 72.2%. The y-axis is labeled as percentage of patients, ranging from 0% to 100%. The chart visually demonstrates higher patient percentage in the Levetiracetam group compared to Placebo.*

FDA Label Image

Image 07

Packaging label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) concentrate solution for intravenous injection by TAGI Pharma, Inc. The label indicates 10 single-dose 5 mL vials per package. It includes directions for intravenous use only, noting the solution must be diluted prior to administration. The label displays the NDC 51224-013-10 and manufacturer information in South Beloit, IL.*

FDA Label Image

Image 08

Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) injection solution concentrate for intravenous use. This label is for a carton containing 25 single-dose 5 mL vials. The product is manufactured for TAGI Pharma, Inc., South Beloit, IL. The label states the product is Rx only and must be diluted prior to administration.*

FDA Label Image

Levetiracetam

Chemical structure of levetiracetam, the active ingredient in Levetiracetam injection, solution, concentrate 100 mg/mL by TAGI Pharma, Inc. The structure shows a pyrrolidone ring with ethyl and amide substituents.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.